Additional Information
Book Details
Abstract
The fifth edition of our flagship publication (Palliative Care Formulary) is now available. As well as including updated monographs, this new edition also contains selected information from the now discontinued Symptom Management in Advanced Cancer. Since the publication of PCF4 in 2011, every drug monograph has been reviewed and updated. Two new chapters cover variability in response to drugs (replaces chapter on Cytochrome P450) and the drug treatment of pruritus. To aid comparison, several sets of drug monographs have been streamlined into single generic monographs, notably Bisphosphonates, Cannabinoids, Haemostatics, LMWH, Opioid antagonists, Psychostimulants. Although written primarily with cancer patients in mind, PCF5 contains specific material relating to several other life-limiting diseases e.g. COPD, congestive heart failure, renal failure, and Parkinson's disease. PCF also includes a number of Quick Clinical Guides.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Contents | 4 | ||
| Quick Clinical Guides | 8 | ||
| Disclaimer | 9 | ||
| Editorial staff | 10 | ||
| Preface | 13 | ||
| About www.palliativedrugs.com | 14 | ||
| How PCF is constructed | 15 | ||
| Main changes in PCF5+ PDF 2016 | 17 | ||
| Getting the most out of PCF | 19 | ||
| The use of medicinal products beyond (off-label) and without (unauthorized) marketing authorization | 23 | ||
| Drug names | 31 | ||
| Abbreviations | 33 | ||
| Part 1 Drug Monographs | 38 | ||
| 1: Gastro-intestinal system | 38 | ||
| Antacids | 38 | ||
| Compound alginate products | 41 | ||
| Simeticone | 42 | ||
| Antimuscarinics | 43 | ||
| Quick Clinical Guide: Death rattle (noisy rattling breathing) | 49 | ||
| Glycopyrronium | 50 | ||
| Hyoscine butylbromide | 54 | ||
| Hyoscine hydrobromide | 57 | ||
| Propantheline | 60 | ||
| Orphenadrine | 62 | ||
| Prokinetics | 64 | ||
| H2-receptor antagonists | 69 | ||
| Proton pump inhibitors | 73 | ||
| Loperamide | 78 | ||
| Laxatives | 82 | ||
| Quick Clinical Guide: Opioid-induced constipation | 86 | ||
| Quick Clinical Guide: Bowel management in paraplegia and tetraplegia | 88 | ||
| Ispaghula (Psyllium) husk | 89 | ||
| Stimulant laxatives | 90 | ||
| Docusate sodium | 94 | ||
| Lactulose | 96 | ||
| Macrogols (polyethylene glycols) | 98 | ||
| Magnesium salts | 101 | ||
| Rectal products for constipation | 103 | ||
| Products for haemorrhoids | 105 | ||
| Pancreatin | 107 | ||
| 2: Cardiovascular system | 109 | ||
| Furosemide | 110 | ||
| Spironolactone | 117 | ||
| Systemic local anaesthetics | 121 | ||
| *Clonidine | 127 | ||
| Glyceryl trinitrate | 132 | ||
| Nifedipine | 137 | ||
| Anticoagulants | 140 | ||
| Low molecular weight heparin (LMWH) | 144 | ||
| Quick Clinical Guide: Heparin-Induced Thrombocytopenia (HIT) | 152 | ||
| Haemostatics | 153 | ||
| 3: Respiratory system | 159 | ||
| Bronchodilators | 159 | ||
| Ipratropium bromide | 166 | ||
| Tiotropium | 168 | ||
| Salbutamol | 170 | ||
| Inhaled long-acting b2 agonists (LABAs) | 173 | ||
| Theophylline | 179 | ||
| Inhaled corticosteroids | 183 | ||
| Oxygen | 188 | ||
| Drugs for cough | 198 | ||
| Mucolytics | 201 | ||
| Antitussives | 203 | ||
| 4: Central nervous system | 207 | ||
| Psychotropics | 207 | ||
| Benzodiazepines | 208 | ||
| Diazepam | 217 | ||
| Midazolam | 219 | ||
| Clonazepam | 223 | ||
| Lorazepam | 225 | ||
| Melatonin | 228 | ||
| Antipsychotics | 232 | ||
| Haloperidol | 242 | ||
| Prochlorperazine | 246 | ||
| Levomepromazine | 248 | ||
| Olanzapine | 251 | ||
| Risperidone | 254 | ||
| Quetiapine | 257 | ||
| Antidepressants | 260 | ||
| Quick Clinical Guide: Depression | 279 | ||
| Amitriptyline | 281 | ||
| Nortriptyline | 284 | ||
| Selective serotonin re-uptake inhibitors | 286 | ||
| *Venlafaxine | 291 | ||
| Duloxetine | 294 | ||
| Mirtazapine | 297 | ||
| Trazodone | 300 | ||
| *Psychostimulants | 303 | ||
| *Cannabinoids | 309 | ||
| Anti-emetics | 316 | ||
| Quick Clinical Guide: Management of nausea and vomiting | 322 | ||
| Metoclopramide | 324 | ||
| Domperidone | 329 | ||
| Antihistaminic antimuscarinic anti-emetics | 333 | ||
| Quick Clinical Guide: Vertigo | 336 | ||
| 5HT3 antagonists | 338 | ||
| Anti-epileptics | 342 | ||
| Gabapentin and pregabalin | 359 | ||
| Carbamazepine | 365 | ||
| Oxcarbazepine | 369 | ||
| Valproate | 371 | ||
| Levetiracetam | 376 | ||
| Phenobarbital | 379 | ||
| 5: Analgesics | 384 | ||
| Principles of use of analgesics | 384 | ||
| Adjuvant analgesics | 389 | ||
| Paracetamol | 394 | ||
| Nefopam | 402 | ||
| Non-steroidal anti-inflammatory drugs (NSAIDs) | 404 | ||
| Celecoxib | 426 | ||
| Diclofenac sodium | 430 | ||
| Flurbiprofen | 434 | ||
| Ibuprofen | 437 | ||
| *Ketorolac trometamol | 441 | ||
| Naproxen | 445 | ||
| Nabumetone | 448 | ||
| Weak opioids | 452 | ||
| Codeine phosphate | 454 | ||
| Dihydrocodeine tartrate | 457 | ||
| Tramadol | 459 | ||
| Strong opioids | 465 | ||
| Morphine | 483 | ||
| Diamorphine | 495 | ||
| *Alfentanil | 498 | ||
| Quick Clinical Guide: Management of procedure-related pain | 503 | ||
| Buprenorphine | 505 | ||
| Quick Clinical Guide: Use of transdermal buprenorphine | 515 | ||
| Fentanyl | 517 | ||
| Quick Clinical Guide: Use of transdermal fentanyl patches | 526 | ||
| Fentanyl (transmucosal) | 528 | ||
| Hydromorphone | 548 | ||
| *Methadone | 552 | ||
| Quick Clinical Guide: Use of methadone for cancer pain | 560 | ||
| Oxycodone | 562 | ||
| Tapentadol | 569 | ||
| Opioid antagonists | 572 | ||
| 6: Infections | 582 | ||
| Antibacterials in palliative care | 582 | ||
| Oropharyngeal candidosis | 587 | ||
| Metronidazole | 591 | ||
| Rifampicin | 594 | ||
| Urinary tract infections | 598 | ||
| Cellulitis in a lymphoedematous limb | 604 | ||
| Quick Clinical Guide: Cellulitis in lymphoedema | 608 | ||
| Clostridium difficile infection | 610 | ||
| 7: Endocrine system and immunomodulation | 615 | ||
| Bisphosphonates | 615 | ||
| Systemic corticosteroids | 627 | ||
| Demeclocycline | 640 | ||
| Desmopressin | 644 | ||
| Drugs for diabetes mellitus | 648 | ||
| *Octreotide | 662 | ||
| Progestogens | 669 | ||
| Danazol | 674 | ||
| *Thalidomide | 677 | ||
| 8: Urinary tract disorders | 683 | ||
| Tamsulosin | 683 | ||
| Oxybutynin | 686 | ||
| Methenamine hippurate | 689 | ||
| Cranberry juice | 691 | ||
| Catheter patency solutions | 694 | ||
| Discoloured urine | 696 | ||
| 9: Nutrition and blood | 698 | ||
| Anaemia | 698 | ||
| Ferrous sulfate | 700 | ||
| Ascorbic acid (vitamin C) | 702 | ||
| Phytomenadione (vitamin K1) | 704 | ||
| Potassium | 707 | ||
| Magnesium | 710 | ||
| Zinc | 718 | ||
| 10: Musculoskeletal and joint diseases | 723 | ||
| Depot corticosteroid injections | 723 | ||
| Rubefacients and other topical products | 725 | ||
| Skeletal muscle relaxants | 731 | ||
| Baclofen | 735 | ||
| Dantrolene sodium | 738 | ||
| Tizanidine | 740 | ||
| 11: Ear, nose and oropharynx | 742 | ||
| Mouthwashes | 742 | ||
| Artificial saliva | 744 | ||
| Pilocarpine | 746 | ||
| Drugs for oral inflammation and ulceration | 748 | ||
| Cerumenolytics | 753 | ||
| 12: Skin | 755 | ||
| Emollients | 755 | ||
| Topical antipruritics | 764 | ||
| Barrier products | 769 | ||
| 13: Anaesthesia | 772 | ||
| *Ketamine | 772 | ||
| *Propofol | 784 | ||
| Part 2 General Topics | 789 | ||
| 14: Guidance about prescribing in palliative care | 789 | ||
| 15: Opioid dose conversion ratios | 812 | ||
| 16: Drug treatment in the imminently dying | 820 | ||
| 17: Pre-emptive prescribing in the community | 832 | ||
| 18: Management of postoperative pain in opioid-dependent patients | 837 | ||
| 19: Drugs and fitness to drive | 840 | ||
| 20: Continuous subcutaneous drug infusions | 845 | ||
| 21: Spinal analgesia | 862 | ||
| 22: Drug administration to patients with swallowing difficulties or enteral feeding tubes | 875 | ||
| 23: Nebulized drugs | 901 | ||
| 24: Prolongation of the QT interval in palliative care | 906 | ||
| 25: Variability in response to drugs | 915 | ||
| 26: Drug-induced movement disorders | 930 | ||
| 27: Anaphylaxis | 935 | ||
| 28: Drugs for pruritus | 940 | ||
| 29: Oral nutritional supplements | 949 | ||
| Appendices | 966 | ||
| A1: Obtaining unauthorized (unlicensed) products | 966 | ||
| A2: Taking controlled and prescription drugs to other countries | 968 | ||
| A3: Compatibility charts | 970 |